M.D., Director of Cancer Genomics, Intermountain Healthcare
Dr. Lincoln Nadauld, MD/PhD, was most recently hired to head the new cancer genomics department at Intermountain Healthcare’s first in-house cancer genomic program. Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees (MD/PhD) followed by internship and residency at the University of Utah. His doctoral dissertation focused on the molecular genetics of colon cancer. He completed a fellowship in medical oncology at Stanford University where he remained as faculty at the Stanford School of Medicine focusing on cancer genomics and personalized cancer medicine. While at Stanford, he helped to develop technologies that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient. Last year Dr. Nadauld was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute.
Session: Expediting Genomics into the Clinic
The widespread clinical application of personalized genomic medicine has historically been hampered by several important factors, including data interpretation, the high cost of testing, and the extended turnaround times associated with in-depth genomic analysis. Expediting these technologies into clinical practice for the benefit of patients is the topic of this session. Panelists will discuss the clinical applications of genomic medicine and share insights regarding the barriers and opportunities to moving genomics into regular clinical practice.